Gemox as First and Second Line Therapy in Unknown Primary Cancer
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Primary objectives:
1. To determine the overall tumor response rate with oxaliplatin in combination with
gemcitabine (GEMOX) as first line and second line therapy in unknown primary cancer
(UPC).
2. To determine the tolerability (toxicity) of this regimen in this patient population.
Secondary objectives:
1. To determine the median overall survival (OS) and time to progression (TTP) for patients
treated with this combination.
2. To determine the impact of this combination on quality of life (QOL) in this patient
population.